Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check5 days agoChange DetectedThe Study Locations section was updated: new sites were added across several U.S. states and international locations (e.g., Alabama, Arkansas, California, Colorado, Florida, Missouri, Ohio, Tennessee, Texas, Virginia, Tel Aviv, Chiba, Tokyo, Gyeonggido, Seoul Teugbyeolsi), and several existing sites were removed.SummaryDifference2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA minor revision update indicates version v3.3.2 was published; no changes to core study content, eligibility, outcomes, or locations are evident in the visible page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedThe page now displays Revision: v3.3.1, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded Tainan, Taiwan, 704 to the Locations section. Replaced the listing 'Tainan City, Taiwan, 704' with 'Tainan, Taiwan, 704' to reflect corrected locality naming.SummaryDifference0.4%

- Check55 days agoChange DetectedNo substantive content changes detected on the Study Details page; updates appear to be UI/formatting adjustments without changes to core sections such as eligibility criteria or outcome measures — To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center (high importance). - Updated version to v3.2.0; removed v3.1.0 reference.SummaryDifference4%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.